Home / Pharmaceuticals / Anticoagulant Reversal Drugs Market By Drug Class (Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexmic Acid, Desmopressin, Idarucizumab, Andexxa) - Growth, Future Prospects And Competitive Landscape, 2018 – 2026

Anticoagulant Reversal Drugs Market By Drug Class (Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexmic Acid, Desmopressin, Idarucizumab, Andexxa) - Growth, Future Prospects And Competitive Landscape, 2018 – 2026

Published: Mar 2019 | Report Code: 59602-03-19

Industry Outlook

The global anticoagulant reversal drugs market expected to grow at compound annual growth rate (CAGR) of 15.3% during the forecast period from 2018 to 2026. Reversing the effects of anticoagulants including novel oral anticoagulants (NOACs), Vitamin K antagonist and others is a major concern in clinical practice especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in last decade has increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT). However, this growth in anticoagulants usage has led to the rise in the incidence of hospitals admissions and death due to increased bleeding due to anticoagulation. According to Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in U.S. alone and close to 2,000 deaths per month attributable to anticoagulation or factor Xa inhibitor related bleeding. These factors have led to furious research and development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) has granted special status and accelerated approvals for development and swift market entry of certain anticoagulant antidotes.

Market Synopsis

Anticoagulant Reversal Drugs Market

Get a sample copy for more information

"Recent Approval of First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market"

In May 2018, The U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing of anticoagulation effects. Andexxa received both orphan drug status and breakthrough designation by U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it to grow at fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drugs market owing to increased use of these agents during critical situation. Idarucizumab, approved in 2015 was the only drug for reversing the anticoagulation effects of dabigatran etexilate mesylate.

Anticoagulant Reversal Drugs Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Anticoagulant reversal drugs market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Drug Class (2016–2026; US$ Mn)
 • Prothrombin Complex Concentrates (PCC)
 • Vitamin K
 • Protamine
 • Tranexmic Acid
 • Desmopressin
 • Idarucizumab
 • Andexxa
 • Pipeline Analysis
 • Phase III Drugs (Forecast till 2026)
   o Octaplex
 • Phase I and II Drugs (Tabular Representation)

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Market is studied in order to understand the current dynamics and future trends in the global anticoagulant reversal drugs market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc. and Ferring Pharmaceuticals.


Anticoagulant Reversal Drugs Market

Get a sample copy for more information

Key questions answered in this report

  • How the global anticoagulant reversal drugs market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the anticoagulant reversal drugs market and valuable opportunities for key players?
  • Who are the leading players in the global anticoagulant reversal drugs market?
  • Which is the leading and fastest region in the global anticoagulant reversal drugs market?
  • What are drivers and restrains governing the global anticoagulant reversal drugs market?
  • What is the pipeline of anticoagulant reversal drugs market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global ARD Market Portraiture
2.2. Global ARD Market, by Drug Class, 2017 (US$ Mn)
2.3. Global ARD Market, by Geography, 2017 (US$ Mn)

Chapter 3. Anticoagulant Reversal Drugs (ARD): Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global ARD Market, by Key Players, 2017

Chapter 4. Global Anticoagulant Reversal Drugs (ARD) Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Prothrombin Complex Concentrates (PCC)
4.3. Vitamin K
4.4. Protamine
4.5. Tranexmic Acid
4.6. Desmopressin
4.7. Idarucizumab
4.8. Andexxa
4.9. Pipeline Analysis
4.9.1. Phase III Drugs
4.9.1.1. Octaplex
4.9.2. Phase I and II Drugs (Tabular Representation)

Chapter 5. Global Anticoagulant Reversal Drugs (ARD) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. North America ARD Market Analysis, 2016 – 2026
5.1.1. North America ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.1.2. North America ARD Market, by Country, 2016 – 2026 (US$ Mn)
5.1.2.1. U.S.
5.1.2.2. Canada
5.2. Europe ARD Market Analysis, 2016 – 2026
5.2.1. Europe ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.2.2. Europe ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.2.2.1. U.K.
5.2.2.2. Germany
5.2.2.3. Rest of Europe
5.3. Asia Pacific ARD Market Analysis, 2016 – 2026
5.3.1. Asia Pacific ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.3.2. Asia Pacific ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. China
5.3.2.2. Japan
5.3.2.3. Rest of Asia Pacific
5.4. Latin America ARD Market Analysis, 2016 – 2026
5.4.1. Latin America ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.4.2. Latin America ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East & Africa ARD Market, 2016 – 2026
5.5.1. Middle East & Africa ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.5.2. Middle East & Africa ARD Market, by Region, 2016 – 2026 (US$ Mn)
5.5.2.1. GCC
5.5.2.2. Rest of Middle East & Africa

Chapter 6. Company Profiles
6.1. Boehringer Ingelheim GmbH
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Fresenius Kabi AG
6.3. Pfizer, Inc.
6.4. Bausch Health Companies, Inc.
6.5. Amneal Pharmaceuticals, Inc.
6.6. CSL Behring Limited
6.7. Octapharma AG
6.8. Portola Pharmaceuticals, Inc.
6.9. Perosphere Pharmaceuticals, Inc.
6.10. Ferring Pharmaceuticals

Note :

Modification in the list of company profiles or scope of the study can be incorporated on request.

* ARD - Anticoagulant Reversal Drugs

FIG 1. Anticoagulant Reversal Drugs (ARD) Market: Research Methodology
FIG 2. ARD: Market Segmentation
FIG 3. Global ARD Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global ARD Market, by Geography, 2017 (US$ Mn)
FIG 5. Attractive Investment Proposition, by Geography, 2017
FIG 6. Competitive Analysis: Global ARD Market, by Key Players, 2017
FIG 7. Global Prothrombin Complex Concentrates (PCC) for ARD Market, 2016-2026 (US$ Mn)
FIG 8. Global Vitamin K for ARD Market, 2016-2026 (US$ Mn)
FIG 9. Global Protamine for ARD Market, 2016-2026 (US$ Mn)
FIG 10. Global Tranexmic Acid for ARD Market, 2016-2026 (US$ Mn)
FIG 11. Global Desmopressin for ARD Market, 2016-2026(US$ Mn)
FIG 12. Global Idarucizumab for ARD Market, 2016-2026(US$ Mn)
FIG 13. Global Andexxa for ARD Market, 2016-2026(US$ Mn)
FIG 14. Global Octaplex for ARD Market, (US$ Mn)
FIG 15. U.S. ARD Market, 2016-2026 (US$ Mn)
FIG 16. Canada ARD Market, 2016-2026 (US$ Mn)
FIG 17. U.K. ARD Market, 2016-2026 (US$ Mn)
FIG 18. Germany ARD Market, 2016-2026 (US$ Mn)
FIG 19. Rest of Europe ARD Market, 2016-2026 (US$ Mn)
FIG 20. China ARD Market, 2016-2026 (US$ Mn)
FIG 21. Japan ARD Market, 2016-2026 (US$ Mn)
FIG 22. Rest of Asia Pacific ARD Market, 2016-2026 (US$ Mn)
FIG 23. Brazil ARD Market, 2016-2026 (US$ Mn)
FIG 24. Mexico ARD Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Latin America ARD Market, 2016-2026 (US$ Mn)
FIG 26. GCC ARD Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Middle East & Africa ARD Market, 2016-2026 (US$ Mn)

TABLE 1 Global Anticoagulant Reversal Drugs (ARD) Market Portraiture
TABLE 2 Global ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Phase I and II Drug for ARD Market
TABLE 4 Global ARD Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 North America ARD Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 8 Europe ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East & Africa ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 14 Middle East & Africa ARD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 15 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Fresenius Kabi AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Bausch Health Companies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Amneal Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 CSL Behring Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Octapharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Portola Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Perosphere Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Ferring Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients